Reference : Pre-study and in-study validation of a SPE-LC-MS-MS method for the determination of 5...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/105127
Pre-study and in-study validation of a SPE-LC-MS-MS method for the determination of 5-S-cysteinyldopa, a melanoma biomarker, in human plasma.
English
Martin, Gaelle [> > > >]
Mansion, François mailto [Université de Liège - ULg > Département de pharmacie > Analyse des médicaments]
Houbart, Virginie [Université de Liège - ULg > Département de pharmacie > Analyse des médicaments]
PAQUET, Philippe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatologie]
RORIVE, Andrée mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale]
CHIAP, Patrice mailto [Centre Hospitalier Universitaire de Liège - CHU > > Pharmacologie clinique >]
Crommen, Jacques mailto [Université de Liège - ULg > Département de pharmacie > Département de pharmacie]
Servais, Anne-Catherine mailto [Université de Liège - ULg > Département de pharmacie > Analyse des médicaments]
Fillet, Marianne mailto [Université de Liège - ULg > Département de pharmacie > Analyse des médicaments]
2011
Talanta
Elsevier Science
84
2
280-6
Yes (verified by ORBi)
International
0039-9140
1873-3573
Amsterdam
The Netherlands
[en] Calibration ; Chromatography, Liquid/methods ; Cysteinyldopa/blood ; Humans ; Limit of Detection ; Melanoma/blood ; Reference Standards ; Reproducibility of Results ; Solid Phase Extraction/methods ; Tandem Mass Spectrometry/methods ; Tumor Markers, Biological/blood
[en] The incidence of malignant melanoma has increased over the past decades, particularly in Caucasian population. This disease presents defavourable prognosis in terms of survey, especially when detection occurs at the metastatic phase. Reliable analytical methods for biomarker determination are thus an interesting tool in pathology detection and follow-up. In this context, a method using SPE-LC-ESI-MS-MS for the determination of 5-S-cysteinyldopa (5-SCD) in human plasma was optimized. The presence of matrix effect was investigated in details while 5-SCD stability was studied according to FDA requirements for the validation of bioanalytical methods. Pre-study and in-study validations of the entire method were then successfully performed by applying the approach based on total measurement error and accuracy profiles over a concentration ranges from 1.6 to 200 ng/ml. Good results with respect to accuracy, trueness and precision were obtained. The maximum risk of observing future measurements falling outside the acceptance limits during routine analysis was also estimated.
http://hdl.handle.net/2268/105127
10.1016/j.talanta.2010.12.047
Copyright (c) 2011 Elsevier B.V. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Martin, Talanta 2011, 84, 280-286.pdfPublisher postprint459.79 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.